Adial Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $24.06 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-12-31 was $169.06K, a 16.59% increase year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-09-30 was $10.00K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-06-30 was -$1.02K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2023-03-31 was -$153.98K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $24.06K, a 86.25% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $175.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $169.06K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $179.06K derived: sum of 2 quarters · filed 2024-04-01 | $178.04K derived: sum of 3 quarters · filed 2024-04-01 | $24.06K 10-K · filed 2024-04-01 |
| 2023-09-30 | $10.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $8.98K derived: sum of 2 quarters · filed 2023-11-14 | -$145.00K 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | -$1.02K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | -$155.00K 10-Q/A · filed 2023-10-30 | -$10.00K derived: sum of 3 quarters · filed 2023-10-30 | -$155.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | -$153.98K 10-Q · filed 2023-05-12 | -$8.98K derived: sum of 2 quarters · filed 2023-05-12 | -$153.98K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $175.00K 10-K · filed 2023-03-30 | |
| 2022-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $30.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $175.00K 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |